4 documents found, page 1 of 1
Global Prevalence of Aspirin Use for Primary Prevention of Cardiovascular Disea...
Yoo, SGK; Chung, GS; Bahendeka, SK; Sibai, AM; Damasceno, A; Farzadfar, F; Rohloff, P; Houehanou, C; Norov, B; Karki, KB; Azangoukhyavy, M; Marcus, METhe role of aspirin in the primary prevention of atherosclerotic cardiovascular disease (CVD) is not clear, with recent clinical trials evaluating aspirin for primary prevention demonstrating both modest benefits and risks associated with its use [1]. Aspirin is not routinely recommended for primary prevention of CVD. Understanding patterns of aspirin use can inform strategies to promote guideline-concordant th...
Global age-sex-specific mortality, life expectancy, and population estimates in...
Schumacher, AE; Kyu, HH; Aali, A; Abbafati, C; Abbas, J; Abbasgholizadeh, R; Abbasi, MA; Abbasian, M; Abd ElHafeez, S; Abdelmasseh, M; Abd Elsalam, SBackground: Estimates of demographic metrics are crucial to assess levels and trends of population health outcomes. The profound impact of the COVID-19 pandemic on populations worldwide has underscored the need for timely estimates to understand this unprecedented event within the context of long-term population health trends. The Global Burden of Diseases, Injuries, and Risk Factors Study (GBD) 2021 provides n...
Worldwide trends in underweight and obesity from 1990 to 2022: A pooled analysi...
Robinson, L; Roccaldo, R; Rodrigues, D; Rodriguez Perez, MdC; Rodríguez Villamizar, LA; Rodríguez, AY; Roggenbuck, U; Rohloff, P; Rohner, FBackground: Underweight and obesity are associated with adverse health outcomes throughout the life course. We estimated the individual and combined prevalence of underweight or thinness and obesity, and their changes, from 1990 to 2022 for adults and school-aged children and adolescents in 200 countries and territories. Methods: We used data from 3663 population-based studies with 222 million participants that...
Aspirin for Secondary Prevention of Cardiovascular Disease in 51 Low-, Middle-,...
Yoo, SGK; Chung, GS; Bahendeka, SK; Sibai, AM; Damasceno, A; Farzadfar, F; Rohloff, P; Houehanou, C; Norov, B; Karki, KB; Azangou-Khyavy, M; Marcus, ME"Importance Aspirin is an effective and low-cost option for reducing atherosclerotic cardiovascular disease (CVD) events and improving mortality rates among individuals with established CVD. To guide efforts to mitigate the global CVD burden, there is a need to understand current levels of aspirin use for secondary prevention of CVD. Objective To report and evaluate aspirin use for secondary prevention of CVD a...